Herantis Pharma Oyj Cash Flow Conversion Efficiency

Latest as of June 2025: -1.937x

Herantis Pharma Oyj cash flow conversion efficiency. Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) has a cash flow conversion efficiency ratio of -1.937x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.39 Million ≈ $-3.96 Million USD) by net assets (€1.75 Million ≈ $2.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Herantis Pharma Oyj (2012–2024)

Cash flow conversion efficiency of Herantis Pharma Oyj from 2012 to 2024. This chart illustrates how Herantis Pharma Oyj's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Herantis Pharma Oyj share price for real-time trading data and today's change.

Herantis Pharma Oyj Cash Flow Conversion Ratio Explained

Herantis Pharma Oyj cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Herantis Pharma Oyj Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Herantis Pharma Oyj ranked by their cash flow conversion efficiency. Also see Herantis Pharma Oyj (HRTIS) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Logistea A ST:LOGI-A	0.020x
Hana Must SPAC 2 KQ:208370	0.013x
DNA Biomed Solns TA:DNA	-0.003x
Harvard Bioscience Inc NASDAQ:HBIO	0.044x
Samkee Automotive Co. Ltd KQ:122350	0.044x
Pacific Orient Bhd KLSE:6009	-0.205x
WESTBRIDGE RE. EN. CORP. F:PUQ	N/A
Coventry Group Ltd AU:CYG	0.024x

Annual Cash Flow Conversion Efficiency for Herantis Pharma Oyj (2012–2024)

The table below shows the annual cash flow conversion efficiency of Herantis Pharma Oyj from 2012 to 2024. Review cash generation quality of Herantis Pharma Oyj to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€-243.00K ≈ $-284.09K	€-6.54 Million ≈ $-7.65 Million	26.934x	+2845.91%
2023-12-31	€4.73 Million ≈ $5.53 Million	€-4.64 Million ≈ $-5.42 Million	-0.981x	-100.66%
2022-12-31	€-60.28K ≈ $-70.48K	€-8.94 Million ≈ $-10.46 Million	148.365x	+927.89%
2021-12-31	€554.30K ≈ $648.04K	€-9.93 Million ≈ $-11.61 Million	-17.921x	-1488.32%
2020-12-31	€7.59 Million ≈ $8.87 Million	€-8.56 Million ≈ $-10.01 Million	-1.128x	+64.95%
2019-12-31	€1.85 Million ≈ $2.16 Million	€-5.96 Million ≈ $-6.97 Million	-3.219x	-107.70%
2018-12-31	€-89.29K ≈ $-104.39K	€-3.73 Million ≈ $-4.36 Million	41.801x	+6678.70%
2017-12-31	€4.09 Million ≈ $4.78 Million	€-2.60 Million ≈ $-3.04 Million	-0.635x	+67.04%
2016-12-31	€1.57 Million ≈ $1.84 Million	€-3.04 Million ≈ $-3.55 Million	-1.928x	-56.32%
2015-12-31	€6.00 Million ≈ $7.01 Million	€-7.40 Million ≈ $-8.65 Million	-1.233x	-514.33%
2014-12-31	€21.72 Million ≈ $25.39 Million	€-4.36 Million ≈ $-5.10 Million	-0.201x	+89.26%
2013-12-31	€120.00K ≈ $140.29K	€-224.21K ≈ $-262.13K	-1.868x	-101.18%
2012-12-31	€-3.37K ≈ $-3.94K	€-533.42K ≈ $-623.62K	158.097x	--

About Herantis Pharma Oyj

HE:HRTIS Finland Biotechnology

Market Cap

$36.44 Million

€31.17 Million EUR

Market Cap Rank

#22853 Global

#115 in Finland

Share Price

€1.18

Change (1 day)

-0.84%

52-Week Range

€1.15 - €2.56

All Time High

€10.10